AquaAdvantage Salmon Lisa Danielson. Outline Introduction Explanations Significance Research Question Methodology My approach Literature Review Problems.

Slides:



Advertisements
Similar presentations
Inadequacies in the Federal Regulation of Agricultural Biotechnology Gregory Jaffe Director, Biotechnology Project Center for Science in the Public Interest.
Advertisements

GREEN IRELAND. BRANDING FOR FARMING, FOOD AND ECO-TOURISM.
Indoor Tanning Association Dan Humiston President.
Brian Ellis Biotechnology Laboratory - UBC May 02, 2001.
+ The Food We Eat How much do you really know about the food that you eat and how it is made? Would you ever eat something that was created in a laboratory.
Facility Design Tutorial This tutorial is designed to enhance knowledge of biotechnological/pharmaceutical processes. The topics covered within this tutorial.
Consumer Reactions to Products of New Animal Technologies Presentation to: Advisory Committee on Biotechnology and 21 st Century Agriculture (AC21) November.
Current Perspectives on Biotechnology: Projects and Future Challenges/Opportunities Jordan BeanDr. Jaimie Schnell Novel Foods SectionPlant Health and Biotechnology.
Regulation and Safety Assessment of Novel Foods in Canada William Yan, Ph.D. Office of Food Biotechnology Health Canada.
PROGRESS REPORT II AquAdvantage Salmon Lisa Danielson.
Genetic Engineering. Tools for Manipulating & Studying DNA  Restriction enzymes  Used to cut DNA where needed  PCR  Used to make multiple copies of.
Genetics E.Q.: How much control do humans really have? C.Q.: How can knowledge of genetics change the way we feed the world?
What Do Toxicologists Do?
Safety and Regulation in Agricultural Biotechnology MUPGRET Workshop.
Jeff Jones, DVM, PhD Animal Biotechnology Interdisciplinary Group Center for Veterinary Medicine U.S. Food and Drug Administration Regulation of Genetically.
FDA’s Policy for Evaluating Bioengineered Foods Jeanette Glover Glew Food and Drug Administration Center For Food Safety and Applied Nutrition September,
Ohio Nano-Summit March 3, 2005 REGULATORY CONSIDERATIONS FOR NANOTECHNOLOGY IN PUBLIC HEALTH FOOD AND DRUG ADMINISTRATION Norris E. Alderson, Ph.D. Associate.
Risk and Resilience: A Canadian Perspective on Climate Change Adaptation Donald S. Lemmen, PhD Climate Change Impacts and Adaptation Directorate Natural.
The Role of Biotechnology in a Sustainable Food Supply Section 3 : Risk Assessment Peggy G. Lemaux, University of California, Berkeley, California, U.S.A.
Malini M. Wileman, PhD, RAC Animal Biotechnology Interdisciplinary Group Center for Veterinary Medicine U.S. Food and Drug Administration Regulation of.
Mrs. Brandi Robinson Office of New Animal Drug Evaluation Center for Veterinary Medicine Regulating Animal Drugs.
Natural Resource Concerns. In 2007 there were a number of food borne illness attributed to fresh produce People became sick Business’s lost market share.
A Consumer Perspective on Biotech Foods Gregory Jaffe Director, Biotechnology Project Center for Science in the Public Interest October 7, 2004.
Societal Perspectives on Agricultural Biotechnology Dr. Thomas J. Hoban Professor of Sociology and Food Science NC State University Invited presentation.
GMO. What are GMOs? GMOs are plants or animals whose cells have been inserted with a gene from an unrelated species in order to take on specific characteristics.
Labeling of Genetically Engineered Foods Pat Byrne Department of Soil & Crop Sciences Colorado State University.
“PRECAUTION AND THE REGULATION OF LIVING MODIFIED ORGANISMS (LMOs)” EMMA ISSATT.
Genetically Modified Organisms in Agricultural Production.
Consumer perceptions of risk, benefit and risk management - Emerging themes in European research Dr Lynn Frewer Professor, Food Safety and Consumer Behaviour.
Regulatory Procedure for the Assessment of GM Foods.
Center for Drug Evaluation and Research August 2005 Electroretinography: The FDA’s Viewpoint Wiley A. Chambers, MD Deputy Director Division of Anti-Infective.
REGULATORY CHALLENGES FOR NANOMATERIALS IN PUBLIC HEALTH Driving Faster Than Our Nano-Headlights AAAS Annual Meeting February 13, 2009 Norris E. Alderson,
Understanding modern farming techniques and sustainable alternatives.
Introduction to GMOs: Myths and realities Masami Takeuchi, Ph.D. Food Safety Officer.
ENVR 401 December 1, 2003 Supervisor: George McCourt Ashleigh Akalehiywot Andrea Hicks Mara Dacso Ted Walker Lillian Harris Kate Washington Regulation.
Salmon Or Progress Report 4 Lisa Danielson February 2 nd, 2011.
Review of veterinary medicines legislation in 2010 Mario Nagtzaam Unit F2 „Pharmaceuticals“ Directorate-General Enterprise and Industry European Commission.
Issues and Ethics in Biotechnology
Biotechnology. D Biotechnology2 Definition Techniques used to modify deoxyribonucleic acid (DNA) or the genetic material of a microorganism, plant,
Environmental Assessment of Genetically Engineered Animals at CVM (FDA) Animal Biotechnology Interdisciplinary Group Center for Veterinary Medicine U.S.
Nanotechnology - USDA - 18 Nov 2002 REGULATORY CONSIDERATIONS FOR NANOTECHNOLOGY IN PUBLIC HEALTH FOOD AND DRUG ADMINISTRATION Norris E. Alderson, Ph.D.
1 Wuyang Hu, Michele Veeman, Vic Adamowicz Dept. of Rural Economy University of Alberta Anne Huennemeyer KFW Group, Germany Financial assistance from Genome.
Aquaculture and fish cell technology
Regulation of Biopharmaceuticals in Canada Environmental Research ENVR 401 Supervisor George McCourt Oct. 16, 2003.
Genetically Modified Foods Beth Roberson November 19, 2004 FST 490.
Genetically Modified Organisms-GMO
Environmental Assessment of Genetically Engineered Animals at CVM (FDA) Animal Biotechnology Interdisciplinary Group Center for Veterinary Medicine U.S.
Significance of this decision Final stage of approval First time FDA would approve a genetically modified (GM) organism for human consumption.
GMO Salmon: A risky solution in search of a problem Tim Schwab Senior Researcher, Food & Water Watch Tulane University February 19, 2016.
The Benefits of VICH to VICH Member Countries and Regions DONALD A. PRATER, DVM Director, U.S. FDA Europe Office Office of International Programs Office.
GMO Fact or Fiction?. Fact or Fiction? GMOs are created by injecting chemicals into food AFTER it is harvested Fiction GMOs are developed through genetic.
Critiquing Quantitative Research.  A critical appraisal is careful evaluation of all aspects of a research study in order to assess the merits, limitations,
Public Perceptions of Agricultural Biotechnology In the United States in William K. Hallman, PhD. Food Policy Institute Rutgers University.
Biotechnology North Carolina. Biotechnology Terms.
GENETICALLY MODIFIED ORGANISM (GMO) TECHNOHOLICS.
It’s a food… It’s a drug… It’s AquAdvantage Salmon! Ricardo Carvajal Hyman, Phelps & McNamara, P.C st Annual Tulane.
Genetically Engineered Foods: Overview
Grade A Dairy Equivalence
Genetically Modified Organism (GMO)
WORKSHOP ON CULTURAL AND RELIGIOUS ISSUES SURROUNDING GMO’S
ISSUES SURROUNDING GENETICALLY MODIFIED ORGANISMS (GMOs):
Genetically Modified Food
Social and Ethical Considerations of Agro-biotechnology
Aquadvantage Salmon Jake DeVore 5/11/18
Board on Agriculture and Natural Resources
The Plant World and Genetic Engineering
A Genetically Modified Solution?
FDA Regulation of Animal Biotechnology Products
Presentation transcript:

AquaAdvantage Salmon Lisa Danielson

Outline Introduction Explanations Significance Research Question Methodology My approach Literature Review Problems and Questions

The AquaAdvantage Salmon What is it? Atlantic salmon modified with a growth hormone adapted from the Chinook Salmon and an anti-freeze gene adapted from Sea Pout. + Why? The salmon grows twice as fast as regular Atlantic salmon and can be raised in colder waters.

Why talk about this now? The FDA is currently deciding if the AquaBounty can sell the eggs to fish farmers The Panel discussion started on Sept 19 th and was supposed to last for 3 days but has been prolonged. They are discussing the proposals science based issues, such as environmental impacts and possible health concerns Upstream research: examining the issue while it is being approved Initial media frenzy

Something Fishy ? Substantial equivalence : The concept a novel food ( such as a GMO food) should be considered to be equivalent and as safe as a conventional food if it demonstrates the same characteristics and composition as the conventional food  If a novel food is substantially equivalent to its conventional counterpart, then it can be encompassed in existing regulatory frameworks Policy for regulating the Salmon will be the same as used for veterinary drugs “AquAdvantage® Salon are regulated by the Center for Veterinary Medicine under the Food, Drug and Cosmetics Act. As far back as 1986, the U.S. Food and Drug Administration (FDA) asserted jurisdiction over genetically engineered animals and fish on the grounds that the transgene and any expressed proteins, affect the “structure and function” of the receiving animal analogous to the modalities of veterinary drug formulations. FDA jurisdiction has been upheld by the federal courts.” ( Fish eggs are going to manufactured in Canada (in the PEI facility) and then the fish will be grown in Panama before they are shipped to the US

Why Do We Care? This is the first genetically altered animal up for approval for human consumption. This policy decision will set a precedent. For Canadians: Aquqculture is a huge industry in Canada  we produce 110 tons of farmed salmon a year. Questions of Canadian policy - Will health Canada follow the FDA’s decision? Canadian involvement: the technology is manufactured in PEI but we are not benefiting from it. For you: If this approval goes through GM salmon will probably not be labeled, meaning it could very easily end up on your plate. Is that acceptable?

My Question Given the scales of impact of the approval of this product, is current regulatory procedures in the US adequately equipped to make this decision?

My Approach 1.A Normative Analysis of the Technology What are the environmental impacts? What are the health risks? What are the socioeconomic concerns? What are the ethical implications?

Evaluation of the regulatory process Does the FDA’s process meet these concerns? Public involvement and transparency (the labeling dispute) Potential comparison with Canada

Democratic survey Does the regulation process reflect peoples opinions? Potential survey opportunity What is shaping public opinion? Is it well informed?

Literature Review Ethical and Social Concerns: Dawkins, Rollin Policy of Risk and Regulation: Hoberg, Harrison Existing reviews of risk associated with transgenic salmon: Factors to consider before production and commercialization of aquatic genetically modified organisms: the case of transgenic salmon: Le Curieux-Belfond,Olivier; Vandelac,Louise; Caron,Joseph; Séralini,Gilles- ÉricSource: Environ.Sci.& Policy, 2009, 12, 2, Democratic concerns and public perception: newspaper articles, Atwood FDA meeting material : ls/VeterinaryMedicineAdvisoryCommittee/ucm htm

Some Hunches -The potential benefits of this technology outweigh the risks -With that said - Current regulatory process lack transparency -Policy needs to be redone to fit this novel technology. Placing into a category it does not belong does not adequately deal with the issue - A problem of public knowledge and perception

Obstacles A very current topic = a lack of literature? Too broad an approach Is a Canada / US comparison useful? More focus on Canada? Should the EU be involved? I have not addressed the issue that there is no regulatory cohesion No personal science background Questions and Suggestions are greatly appreciated!